Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

This is a Phase II randomized, double-blind, placebo controlled, multi-site study of Candin. It is designed to show the efficacy and safety of a 7-dose regimen of Candin over a two-year period in terms of reducing cancer recurrence rate by comparing the recurrence rates between the Candin and the placebo arm. The ratio of the number of subjects who will receive Candin versus placebo will be 3:1. Up to 100 subjects will be screened until 80 subjects are eligible for injection.

NCT Number	NCT05952934
Lead Sponsor	University of Arkansas Collaborators: Highlands Oncology Group, PA, NYU Langone Health
Conditions	Squamous Cell Carcinoma of Head and Neck
Enrollment	100 participants
Start Date	2024-02-12
Primary Completion	2031-07-31 (estimated)
Study Completion	2031-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-08